Preclinical studies indicate that treatment of NSCLC cells with DNMT and HDAC inhibitors enhances interferon-α/β signaling, upregulates components of the antigen presentation machinery, and improves tumor control. This evidence concerns the gene DNMT1 and neoplasm.